‘A special report outlines the challenges — from unleashing the power of mRNA vaccines, to the battle for temporary relief on intellectual-property rights...
‘In the long term, argues Friede, every region needs a facility that fully owns the production know-how and can produce vaccines. The gap is most egregious in Africa, a continent that imports 99% of its vaccines, says Nkengasong. It has only three big vaccine manufacturers. “Can a continent of 1.2 billion — projected to be 2.4 billion in 30 years, where one in four people in the world will be African — continue to import 99% of its vaccines?” Nkengasong asks.’
Read here (Nature, Mar 25, 2021)
